At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Aspirin Supplementation for Pregnancy Indicated Risk Reduction in Nulliparas (ASPIRIN): Neurodevelopmental Follow-up Trial
In Brief
An observational study evaluating Aspirin and Placebo for Neurodevelopmental Abnormality. Completed, enrolled 666 participants across 14 sites in 6 countries.
Detailed Summary
A total of 620 children will be enrolled in this study from six sites in sub-Saharan Africa, South Asia, and Latin America. Half of the children's mothers will have taken aspirin and half will have taken placebo. This will allow the researchers to compare results of the two groups of children and determine if children exposed antenatally to low dose aspirin will have scores on the Bayley Scales of Infant Development-III (BSID-III) examination at 36 months of life (+/-3months) that are not inferior to the child's peers who were not exposed (i.e., by no more than a margin of 4 points).
Study Details
Timeline
Interventions
Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
Participant's mothers were administered placebo throughout their pregnancy with the participant.